The table below shows Nurix Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
$6.25M
$7.89M
$44.06M
$18.45M
$12.59M
$12.09M
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
$84.14M
$86.12M
$78.10M
$69.66M
$55.48M
$48.92M
SG&A
NRIX annual revenue (10-K history)
Nurix Therapeutics, Inc. reported annual revenue of $83.98M for fiscal year 2025. That is up 54.0% from $54.55M in fiscal 2024. Over the 7 fiscal years shown, annual revenue grew from $31.11M (FY 2019) to $83.98M. Figures come from the company's audited annual reports as filed with the SEC.